Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards

Cambridge, UK, 2 November 2018 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel.

Microbiotica was recognised for a year of continued development in the fast-growing microbiome space. This year it has collaborated with Genentech, a member of the Roche group, one of the world’s biggest pharmaceutical companies, to discover, develop and commercialise treatments for patients with inflammatory bowel disease.  The deal could see the Company earn up to $534 million in upfront and milestone payments.

In addition, Microbiotica has partnered with the University of Adelaide to access clinical trial samples to facilitate Microbiotica’s own live bacterial therapeutics discovery programme in ulcerative colitis.

Speaking of the Company’s win, CEO Mike Romanos said: “We are proud to be recognised for the milestones we have achieved this year.  We are only scratching the surface when it comes to unlocking Microbiotica’s potential. This year has been significant for Microbiotica and our team has been instrumental to our achievements, for which I would like to thank them.”

In 2016, Microbiotica was created with £8 million funding from Cambridge Innovation Capital and IP Group to commercialise the ground-breaking research of the Wellcome Trust Sanger Institute. In October, Microbiotica attracted additional equity investment from Seventure Partners, bringing the total invested in the Company to date to £12 million.